Barth syndrome, an X-linked disease associated with cardioskeletal myopathy, neutropenia and organic aciduria, is characterized by abnormalities of cardiolipin species in mitochondria. Diagnosis of the disease is often compromised by lack of rapid and widely available diagnostic laboratory tests.
Introduction
Barth syndrome (BTHS) is a rare, life-threatening, X-linked recessive metabolic disease characterized by infantile or childhood onset of cardiomyopathy, skeletal myopathy, growth delay, neutropenia, 3-methylglutaconic aciduria (3-MGCA), abnormal mitochondrial structure and variable mitochondrial respiratory chain dysfunction (1) (2) (3) (4) . It results from loss-of-function mutations of the tafazzin (TAZ) gene (5) .
The major consequence of this loss-of-function is the deficient remodeling of the mitochondrial phospholipid cardiolipin (CL), a process that normally leads to the mature acyl composition (6) (7) . CL is the signature lipid of mitochondria where it is an important constituent of the inner membrane, essential for supercomplex formation, for oxidative phosphorylation (i.e. mitochondrial energy metabolism), for protein import and capable of triggering mitophagy and mitochondria-mediated apoptosis (8) (9) (10) (11) (12) (13) (14) (15) (16) . Since the remodeling of CL is deficient in BTHS, biochemical abnormalities in patients include a decreased level of mature CL, increased level of monolysocardiolipin (MLCL) and altered CL acyl composition (i.e. the presence of immature species of CL).
Historically, the diagnosis of BTHS has relied on identification of the clinical symptoms accompanied by neutropenia and 3-MGCA, and then confirmed by the finding of TAZ mutations. More recently, assays of CL alone or of the ratio of CL to MLCL have been used in Europe. However, each of these diagnostic approaches has problems. There are multiple reports of false negative disease detection by urinary organic acid screening (4) . TAZ sequencing is relatively slow and expensive and CL analysis involves many steps including extraction of lipids and isolation of CL molecular species by complex chromatographic techniques. Consequently, although measurement of CL/MLCL ratio has 100% diagnostic sensitivity and specificity, it is only available in a few clinical laboratories worldwide (4) . This forms a critical barrier to diagnosis in a disease, which a major Australian study suggested was responsible for 4.8% of all cases of cardiomyopathy in male children (17) . Consequently, in September 2014, only 175 males are known to be living with disease worldwide (data courtesy Barth Syndrome Foundation USA).
Up to now, CL and MLCL analyses in BTHS, with or without diagnostic intent, have been set up on lymphoblasts (18) , lymphocytes (19) , platelets (20) (21) (22) , fibroblasts (23) (24) , neutrophils (25) , leukocytes (26) , bloodspots (27) and tissues (19) . All these reports, including the validated methods (26) (27) , are based on lipid extraction followed by high-performance liquid chromatography (HPLC) and electrospray ionization Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) currently represents a further valid tool in lipid analysis (28) (29) . It has been shown that this emerging analytical technique can be used to directly acquire lipid profiles of biological samples, thus skipping extraction and separation steps (30) (31) (32) (33) . We successfully adopted this experimental approach to describe the lipid composition of bacterial and mitochondrial membranes (30) (31) 33) and to detect lipid markers in blood serum (32) . Importantly, we found that the phosphatidylcholine to lysophosphatidylcholine ratio could be easily determined by MALDI-TOF/MS analyses of native blood serum and followed as a clinical parameter in various diseases (32) . Relevantly, we also reported that CL could be easily detected in direct MALDI-TOF/MS total lipid profiles, by using 9-aminoacridine (9-AA) as matrix (30) , even in the lipid fingerprint of whole cells.
On these bases, we developed a MALDI-TOF/MS method of lipid analysis of intact white blood cells for the clinical monitoring of the MLCL and CL relative levels in BTHS. Moreover, using the method described by Schlame et al. (34) , we used vector algebra to evaluate the differences in CL and MLCL molecular composition of BTHS patients compared to controls.
In our method both blood volume and time required for the analysis can be reduced because lipid extraction and separation can be skipped, simplifying the test. To guarantee the gaining of an informative lipid fingerprint even when using low-performance MALDI-TOF MS instruments, we developed a simple mini lipid-extraction protocol of minute amounts of white blood cell suspension; this additional minor step requires only 10-15 minutes more, significantly increases the signal to noise ratio and increases the resolution of mass spectrometric peaks.
We believe that a rapid, less invasive and novel screening test to monitor CL and its derivatives in blood could be of help in the diagnosis, and has the potential for therapeutic monitoring of BTHS. 
Materials and Methods
Biological samples Blood samples from 24 healthy donors (all males, average age 38.5) and 8 BTHS patients (all males, average age 10.8) were used in the study. In addition, a patient with a recently described ameliorated phenotype has been also analyzed (35) . Samples of healthy donors (CTRL) were obtained with classical blood withdrawal according to institutional guidelines and anonymization, at the Blood Bank of the Policlinic Hospital of Bari. Samples of BTHS patients were obtained during routine venesection for clinical monitoring in patients seen for annual review by the National Health Service (NHS) national UK BTHS clinic at Bristol Royal Hospital for Children. Written informed consent of healthy donors, parents and patients (where appropriate) and approvals by the respective Ethical Committees were obtained.
Isolation of white blood cells
Red blood cells (RBC) were sedimented with the dextran polymer (MW>100 KDa), then hypotonic lysis was applied to eliminate residual RBC. Dextran sedimentation was performed as follows: 0.111 ml of 20% dextran solution (MW>100 kDa, in 0.9% NaCl) was added to 1 ml of whole blood in a 1.5 ml tube. The suspension was pipetted and dispersed gently 20 times with an automatic pipette avoiding air bubbles, which retain RBC at the top of the tube. The yellow supernatant was collected with a syringe, transferred to a 15 ml tube, and then centrifuged at 400 g for 15 min at RT (no brake, swing-bucket rotor).
Hypotonic lysis of residual RBC was performed as follows: after the last centrifugation, the supernatant was discarded and the pellet obtained resuspended in 0.6 ml of iced ddH2O. After 10-15 sec 0.2 ml of 0.6 M KCl was added to the cell suspension to restore the correct osmolarity and then the final volume was adjusted to 2.5 ml with Phosphate Buffered Saline (PBS), containing 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM K2HPO4, pH 7.4. The suspension was then centrifuged at 400 g for 15 min at RT (no brake, swing-bucket rotor). The supernatant was sucked and discarded. The remaining leukocyte pellet was washed again with 2.5 ml PBS, re-collected, resuspended in 200 µL of ddH2O and immediately frozen at -80°C (see Fig. 1 ). Unless otherwise specified lipid analyses performed on frozen samples are reported in the present study.
In our experience, in these conditions, the total protein concentration was >0.9 and <1.8 µg/µl, measured by Bradford assay (Bio-Rad Protein Assay Kit, BioRad Laboratories, Germany).
Mini-extraction of lipids from leukocytes
We set up a modified lipid extraction protocol (the "mini- MALDI-TOF mass spectra were acquired on a Bruker Microflex RLF mass spectrometer (Bruker, Germany) or alternatively on a Bruker Autoflex II, referred to as either Microflex or Autoflex, respectively.
Both systems utilize a pulsed nitrogen laser, emitting at 337 nm; the extraction voltage is 20 kV and gated matrix suppression is applied to prevent detector saturation (up to 400 Th on the Microflex and up to 900 Th on the Autoflex instrument). The laser fluence is kept about 5% above threshold (of CL and MLCL) to have a good signal-to-noise ratio. All spectra were acquired in the reflector mode using delayed pulsed extraction; only spectra acquired in negative ion mode are shown in this study. Baseline correction, peaks areas, isotopologue of the CLm 72:8 and the monoisotopic peak of CLm 72:7 has been introduced. In brief, the X+2 factor of carbon relates to the probability of the ion having two atoms of 13 C. This probability is much smaller than the probability that an ion will have a single atom of 13 C. Consider the binomial expression (a +b) n where a is the percent abundance of the most abundant isotope, b is the abundance of the second isotope of an X+1 element, and n is the number of atoms of the X+1 element. Solving this expansion results in an X+2 factor for the probability of having two atoms of carbon being 0.0060 times the square of the number of carbon atoms (0.006 × nC 2 ). Carbon is usually the most ubiquitous element in ions encountered in organic mass spectrometry; therefore, based on the large numbers of carbon atoms that may be present and the abundance of 13 C, the X+2 factor for carbon can be significant. For a CL having 72 carbons the x+2 factor is 31.1%. In our calculations, we therefore subtracted the 31.1% of the peak area of the CL (18:2)4 from the peak area of the CL (18:2)3(18:1)1.
For a detailed list of assigned CL and MLCL species present in the lipid fingerprints in this study, Table 1 . Sodium adducts were not taken in consideration because their presence was negligible in the lipid profiles considered in the present study. In measurements on intact cells, their presence was minimized by the double wash applied to the final pellet. In measurements on lipid mini-extracts, when samples contained high amounts of sodium adducts, their abundance was reduced by washing the dried sample/matrix spot with cold water. For this purpose, 2 µl of ice-cold water was placed on top of the spot. After a few seconds, the water was sucked up with a small piece of filter paper. The wash was repeated once.
To speed up data analysis we set up an algorithm in MATLAB 7.0 (The MathWorks, Inc.) that automatically elaborate MS spectra exported as (x,y) coordinates in a ASCII file (*.txt). The algorithm can read the exported spectra relative to each subject and calculate the (MLCL+CLi)/CLm ratio as defined. The algorithm is described in details in Supplementary Material (Note 1).
Compositional distance According to Schlame et al. (34) we used vector algebra to compare CL and MLCL molecular compositions of leukocytes from patients and healthy controls considered in our study, as described in the following. By using the statistical analysis of compositional data, we compared the different molecular composition, measuring not only the quality of the differences but also their magnitude. To make this comparison, CL and MLCL molecular composition of each subject (MA, MB, etc.) is considered as a point vector (M) in an n-dimensional space, where n is the number of the molecular species considered. We considered two MLCL species, two mature CL species and two immature CL species, listed in Table 1 . Each point vector M has therefore 5 6 components in the different dimensions M = (m1, m2, m3, m4, m5, m6). The module of these components is given by the signal area of its relative CL or MLCL specie in the lipid profile of the considered subject (average value in at least three spectra). To normalize data, we imposed the condition that the sum of the different components mi must be = 1:
The difference between two molecular compositions MA and MB, can therefore be evaluated as the distance between their respective point vectors (i.e. compositional distance), which is given by the Since mi are normalized fractional intensities, in our conditions the compositional distance can vary from 0 to .
We set up another MATLAB algorithm that can automatically elaborate exported MS spectra and calculate the compositional distance of a suspected patient from the control group, leading to a fast diagnosis. The algorithm is described in details in Supplementary Material (Note 2).
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Results
Cardiolipin fingerprint of healthy donors and BTHS patients
Here we report lipid profiles from control leukocytes obtained by the blood bank of the main hospital in Bari (Italy) and of BTHS patients from Bristol Royal Hospital for Children (UK). Both groups of the samples were prepared by the method described in the Method section. Analyses were performed on frozen samples kept at -80 °C for up to 6 weeks. In preliminary experiments, we found no differences in the lipid profiles of samples stored for 2, 4 or 6 weeks (not shown). seven BTHS patients from three families with TAZ mutations (35) . One of these patients has been also examined with our method. The MALDI-TOF/MS CL fingerprint of the patient without CLm deficiency is reported in Supplementary Materials (Supplemental Fig. 1 ). Compared to the CL fingerprints shown in previous Fig. 2 , it can be seen that in the variant form of BTHS peaks belonging to mature CL species (see Table 1 ) are lower than in the control fingerprint (Fig. 2, upper Figures 2a and 2b , respectively).
It should be considered that not only the presence of MLCL peaks is diagnostic for BTHS but also the presence of immature CL species is typical of this disease. Therefore in the present study we introduced In conclusion (MLCL+CLi)/CLm ratio calculated from MALDI-TOF/MS lipid fingerprint of whole leukocytes is a valid diagnostic parameter to distinguish between controls and BTHS patients. We have also shown that our analytical approach can be employed even with a low-performance mass spectrometer simply by adding the minor mini-extraction step.
Compositional distance as diagnostic parameter
We also used vector algebra to evaluate the effect of the different TAZ mutations on CL and MLCL molecular composition. The statistical approach used is described in the Methods section. Briefly, each different molecular composition is considered as a vector M and distances between the different vectors (i.e. the compositional distance) are used to evaluate differences in CL and MLCL molecular composition of the different subjects in the study. In Figure 5 the compositional distances have been plotted. In the chart, healthy controls have been considered as a unique group and represented as a single point (±SD). For this control group the compositional distance is the average value of the distance between the molecular components of each control subject from all the others. It should be not far from zero since healthy donors Analyzing intact leukocytes by the Bruker Microflex RLF mass spectrometer, BTHS patients resulted sufficiently "distant" from controls, meaning that CL and MLCL molecular composition of patients is sufficiently different from controls to achieve their diagnosis (Fig. 5, panel A) . Nevertheless, with the same instrument, BTHS patients can be neatly distinguished from controls when considering MALDI-TOF mass spectra of the corresponding lipid extracts (panel B).
Finally, a good separation between BTHS patients and controls was obtained by using spectra of intact leukocytes acquired by the Bruker Autoflex II mass spectrometer (panel C).
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Discussion
Diagnosis of Barth syndrome is difficult. Unambiguous diagnostic testing for BTHS can be performed by determination of the relative amounts and distribution of (monolyso-)cardiolipin species and confirmed by TAZ gene sequencing or vice versa. Unfortunately, molecular analysis of the TAZ gene can lead to false negative results when mutations are present in regulating or relevant non-coding sequences; in addition, more than 120 distinct TAZ mutations have been described (4) (5) 36 ).
Furthermore, current lipidomic-based diagnostic tests require relevant experience in HPLC-ESI/MS analysis. Nowadays MALDI-TOF mass spectrometers are widely distributed among clinical laboratories worldwide and do not require high analytical expertise. We have described a simple and fast novel method for measurement of CL in intact leukocytes by MALDI-TOF/MS that requires only 1 ml of blood. As lipid analyses of intact leukocyte membranes may result in poor resolved spectra, as in the case of BTHS 7 and 8 patients in Supplemental Fig. 2a , we have developed a fast method to solubilize lipids and gain a better resolving power. In general, when the S/N ratio of the mass spectrum of intact leukocytes is ≤3, the introduction of the additional step of the mini-extract is highly recommended.
The main advantage of the present method over existing approaches is that it can simultaneously detect diagnostic CL and MLCL species in the total lipid profile by a single run of mass spectrometric analysis immediately after isolation of leukocytes.
Although shotgun lipidomic ESI-MS analysis and quantitation of cellular lipidomes can be directly performed on crude extracts of various biological samples (37) , to the best of our knowledge, this approach
has not yet been used to study CL profiles of whole white blood cells. Direct infusion based ESI-MS approach for gaining a CL fingerprint has been previously used to study lipids of the heart tissue of a BTHS animal model (38) .
The diagnosis for BTHS patients here described relies not only on the decrease of mature CL, but also considers the presence of immature CL species, that together with the raise of MLCL suggest a defect in the of our experimental approach is due to the use of 9-AA as matrix, which is particularly suitable for CLs detection (31) , even when these species are only minor components in complex lipid profiles.
In conclusion the method described here is straightforward to perform and can be easily integrated into 
